Synthetic Approaches to the 2004 New Drugs

Jin, Li; Liu, Kevin K.‐C.; Sakya, Subas M.

doi:10.2174/138955705774933329

Cited by 27 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ibrexafungerp (1), formerly SCY-078 or MK-3118 and developed by Scynexis Inc., is a first-in-class triterpenoid antifungal that inhibits the biosynthesis of β- (1,3)-D-glucan in the fungal cell wall. This mechanism of action provides an opportunity for the treatment of fungal infections that are azole-or echinocandrin-resistant strains.…”

Section: Ibrexafungerp (Brexafemme)mentioning

confidence: 99%

“…The first edition of the “Synthetic Approaches to New Drugs” series was published in 2004 to cover drugs approved in 2002, featuring 28 drugs. This 20th edition will mark the coverage of over 500 new chemical entities (NCEs) that have been approved since the review was initiated, ranging from 12 to over 40 new approved drugs each year. − …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthetic Approaches to the New Drugs Approved During 2021

McInturff,

France,

Leverett

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

Each year, new drugs are introduced to the market, representing structures that have affinity for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody−drug conjugates, provide insight into molecular recognition and serve as potential leads for the design of future medicines. This annual review is part of a continuing series highlighting the most likely process-scale synthetic approaches to 35 NCEs that were first approved anywhere in the world during 2021. ■ SIGNIFICANCEThis publication presents a synopsis of the synthetic approaches to new drugs that were approved in 2021, based on the largest scale of synthesis that has been disclosed in primary literature and/or patents. This provides a view of the practical synthetic methods that are applicable to drug discovery and development and a holistic perspective on the molecular complexity of novel drug molecules and synthetic methods required to manufacture them.

show abstract

Section: Ibrexafungerp (Brexafemme)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Synthetic Approaches to the New Drugs Approved During 2021

McInturff,

France,

Leverett

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…15 Two routes have been reported that describe the preparation of dexlansoprazole on large scale. The first route developed by Takeda reacts commercially available thioether 29, also used to make lansoprazole, under the Kagan asymmetric oxidation conditions 34 35 Thus, the catalyst complex consisting of (+)-DET, Ti(OiPr) 4 and water was formed in the presence of thioether 29 in toluene at 30-40°C. The reaction mixture was then cooled to À5°C and DIPEA and cumene hydroperoxide (CMHP) were added to give, after aqueous work-up and in situ crys- …”

Section: Dexlansoprazole (Dexilant ò )mentioning

confidence: 99%

“…1 Inaugurated eight years ago, this annual review presents synthetic methods for molecular entities that were launched in various countries for the first time during the past year. [2][3][4][5][6][7][8] Given that drugs tend to have structural homology across similar biological targets, it is widely believed that the knowledge of new chemical entities and their syntheses will greatly facilitate drug design. In 2009, 51 new products including new chemical entities, biological drugs, and diagnostic agents reached the market, 9 the largest number in the last decade.…”

Section: Introductionmentioning

confidence: 99%